Jesse D. Bloom

Last updated

Jesse D. Bloom is an American computational virologist and Professor in the Basic Sciences Division, the Public Health Sciences Division, and the Herbold Computational Biology Program, at the Fred Hutchinson Cancer Center. [1] He is also an Investigator of the Howard Hughes Medical Institute, and an Affiliate Professor in the University of Washington departments of Genome Sciences and Microbiology. [2] [3] [4]

Contents

Education and career

Bloom obtained a B.S. in Biochemistry from the University of Chicago, an M.Phil. in Theoretical Chemistry from the University of Cambridge, and a Ph.D in Chemistry from Caltech advised by Frances Arnold. [1] Following his Ph.D., he completed a postdoctoral fellowship in the laboratory of David Baltimore. [5] He became a professor at the Fred Hutchinson Cancer Center in 2011 and an Investigator of the Howard Hughes Medical Institute in 2018. [6] [7]

Research

Bloom’s research focuses on the molecular evolution of viruses and viral proteins, particularly of rapidly-evolving RNA viruses like influenza, HIV, and SARS-CoV-2. [1] [8] [9] [10] His lab uses a combination of computational and experimental techniques to understand how changes in viral proteins result in immune escape, drug resistance, and shifts in host specificity. [2] His group performed the first experimental study showing that human coronaviruses evolve to escape from human antibodies. [11]

Bloom has helped lead the development of deep mutational scanning techniques for measuring the effects of large numbers of mutations in viral proteins in parallel. [8] [10] [12] Notably, his laboratory provided the first map of the effects of mutations in the SARS-CoV-2 spike receptor binding domain on folding and ACE2 affinity. [10] Using the same technique, Bloom’s research group prospectively identified mutations in the SARS-CoV-2 spike protein that erode the immunity provided by both therapeutic antibodies and naturally elicited immune responses. [13] [14] His group has integrated these measurements into an antibody-escape calculator that is used to help track SARS-CoV-2 evolution. [15] They also showed that the ability to bind human ACE2 is widespread and highly evolvable among natural SARS-related coronaviruses, highlighting the zoonotic potential of this family of viruses. [16]

Bloom's scientific work has been published in top scientific journals including Science, Nature, and Cell . [13] [17] [10] [16]

In addition to his scientific publications, Bloom has authored several columns with Sarah Cobey in the New York Times about SARS-CoV-2 evolution. [18] [19]

Bloom has also argued that it is important for virologists to ensure that virology research is performed responsibly and does not create biosafety or biosecurity risks. He outlined his views in a column he published on the topic in the New York Times. [20]

In 2021, Bloom was a co-author of a letter calling for further investigation of COVID-19 origins published in Science. [21] Bloom's research on the origin of COVID-19 "raised the possibility that the Chinese government might be trying to hide evidence about the pandemic’s early spread" and was the subject of a meeting with Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases (NIAID). [22] [23]

Honors and awards

Related Research Articles

<span class="mw-page-title-main">SARS-related coronavirus</span> Species of coronavirus causing SARS and COVID-19

Severe acute respiratory syndrome–related coronavirus is a species of virus consisting of many known strains phylogenetically related to severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) that have been shown to possess the capability to infect humans, bats, and certain other mammals. These enveloped, positive-sense single-stranded RNA viruses enter host cells by binding to the angiotensin-converting enzyme 2 (ACE2) receptor. The SARSr-CoV species is a member of the genus Betacoronavirus and of the subgenus Sarbecovirus.

Antigenic drift is a kind of genetic variation in viruses, arising from the accumulation of mutations in the virus genes that code for virus-surface proteins that host antibodies recognize. This results in a new strain of virus particles that is not effectively inhibited by the antibodies that prevented infection by previous strains. This makes it easier for the changed virus to spread throughout a partially immune population. Antigenic drift occurs in both influenza A and influenza B viruses.

<span class="mw-page-title-main">Angiotensin-converting enzyme 2</span> Exopeptidase enzyme that acts on angiotensin I and II

Angiotensin-converting enzyme 2 (ACE2) is an enzyme that can be found either attached to the membrane of cells (mACE2) in the intestines, kidney, testis, gallbladder, and heart or in a soluble form (sACE2). Both membrane bound and soluble ACE2 are integral parts of the renin–angiotensin–aldosterone system (RAAS) that exists to keep the body's blood pressure in check. While mACE2 does not appear to factor into the harmful phase of RAAS, its existence is vital in order for the enzyme ADAM17 to cleave its extracellular domain to create soluble ACE2 (sACE2). Soluble ACE2 lowers blood pressure by catalyzing the hydrolysis of angiotensin II into angiotensin (1–7) which in turns binds to MasR receptors creating localized vasodilation and hence decreasing blood pressure. This decrease in blood pressure makes the entire process a promising drug target for treating cardiovascular diseases.

<span class="mw-page-title-main">SARS-CoV-1</span> Virus that causes SARS

Severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1), previously known as severe acute respiratory syndrome coronavirus (SARS-CoV), is a strain of coronavirus that causes severe acute respiratory syndrome (SARS), the respiratory illness responsible for the 2002–2004 SARS outbreak. It is an enveloped, positive-sense, single-stranded RNA virus that infects the epithelial cells within the lungs. The virus enters the host cell by binding to angiotensin-converting enzyme 2. It infects humans, bats, and palm civets. The SARS-CoV-1 outbreak was largely brought under control by simple public health measures. Testing people with symptoms, isolating and quarantining suspected cases, and restricting travel all had an effect. SARS-CoV-1 was most transmissible when patients were sick, so its spread could be effectively suppressed by isolating patients with symptoms.

<i>Human coronavirus NL63</i> Species of virus

Human coronavirus NL63 (HCoV-NL63) is a species of coronavirus, specifically a Setracovirus from among the Alphacoronavirus genus. It was identified in late 2004 in patients in the Netherlands by Lia van der Hoek and Krzysztof Pyrc using a novel virus discovery method VIDISCA. Later on the discovery was confirmed by the researchers from the Rotterdam, the Netherlands The virus is an enveloped, positive-sense, single-stranded RNA virus which enters its host cell by binding to ACE2. Infection with the virus has been confirmed worldwide, and has an association with many common symptoms and diseases. Associated diseases include mild to moderate upper respiratory tract infections, severe lower respiratory tract infection, croup and bronchiolitis.

<span class="mw-page-title-main">Joseph DeRisi</span> American biochemist

Joseph Lyman DeRisi is an American biochemist, specializing in molecular biology, parasitology, genomics, virology, and computational biology.

<span class="mw-page-title-main">TMPRSS2</span> Protein-coding gene in the species Homo sapiens

Transmembrane protease, serine 2 is an enzyme that in humans is encoded by the TMPRSS2 gene. It belongs to the TMPRSS family of proteins, whose members are transmembrane proteins which have a serine protease activity. The TMPRSS2 protein is found in high concentration in the cell membranes of epithelial cells of the lung and of the prostate, but also in the heart, liver and gastrointestinal tract.

<span class="mw-page-title-main">SARS-CoV-2</span> Virus that causes COVID-19

Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) is a strain of coronavirus that causes COVID-19, the respiratory illness responsible for the COVID-19 pandemic. The virus previously had the provisional name 2019 novel coronavirus (2019-nCoV), and has also been called human coronavirus 2019. First identified in the city of Wuhan, Hubei, China, the World Health Organization designated the outbreak a public health emergency of international concern from January 30, 2020, to May 5, 2023. SARS‑CoV‑2 is a positive-sense single-stranded RNA virus that is contagious in humans.

<span class="mw-page-title-main">COVID-19</span> Contagious disease caused by SARS-CoV-2

Coronavirus disease 2019 (COVID-19) is a contagious disease caused by the virus SARS-CoV-2. The first known case was identified in Wuhan, China, in December 2019. The disease quickly spread worldwide, resulting in the COVID-19 pandemic.

Allison Joan McGeer is a Canadian infectious disease specialist in the Sinai Health System, and a professor in the Department of Laboratory Medicine and Pathobiology at the University of Toronto. She also appointed at the Dalla Lana School of Public Health and a Senior Clinician Scientist at the Lunenfeld-Tanenbaum Research Institute, and is a partner of the National Collaborating Centre for Infectious Diseases. McGeer has led investigations into the severe acute respiratory syndrome outbreak in Toronto and worked alongside Donald Low. During the COVID-19 pandemic, McGeer has studied how SARS-CoV-2 survives in the air and has served on several provincial committees advising aspects of the Government of Ontario's pandemic response.

<span class="mw-page-title-main">COVID-19 pandemic and animals</span> Overview of the impact of the COVID-19 pandemic on animals

The COVID-19 pandemic has affected animals directly and indirectly. SARS-CoV-2, the virus that causes COVID-19, is zoonotic, which likely to have originated from animals such as bats and pangolins. Human impact on wildlife and animal habitats may be causing such spillover events to become much more likely. The largest incident to date was the culling of 14 to 17 million mink in Denmark after it was discovered that they were infected with a mutant strain of the virus.

<span class="mw-page-title-main">Variants of SARS-CoV-2</span> Notable variants of SARS-CoV-2

There are many variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19). Some are believed, or have been stated, to be of particular importance due to their potential for increased transmissibility, increased virulence, or reduced effectiveness of vaccines against them. These variants contribute to the continuation of the COVID-19 pandemic.

<span class="mw-page-title-main">SARS-CoV-2 variant of concern</span> Highly transmissible and virulent strains of SARS-CoV-2

The term variant of concern (VOC) for SARS-CoV-2, which causes COVID-19, is a category used for variants of the virus where mutations in their spike protein receptor binding domain (RBD) substantially increase binding affinity in RBD-hACE2 complex, while also being linked to rapid spread in human populations.

<span class="mw-page-title-main">SARS-CoV-2 Iota variant</span> Variant of the SARS-Cov-2 virus first identified in New York City

Iota variant, also known as lineage B.1.526, is one of the variants of SARS-CoV-2, the virus that causes COVID-19. It was first detected in New York City in November 2020. The variant has appeared with two notable mutations: the E484K spike mutation, which may help the virus evade antibodies, and the S477N mutation, which helps the virus bind more tightly to human cells.

<span class="mw-page-title-main">SARS-CoV-2 Delta variant</span> Variant of SARS-CoV-2 detected late 2020

The Delta variant (B.1.617.2) was a variant of SARS-CoV-2, the virus that causes COVID-19. It was first detected in India on 5 October 2020. The Delta variant was named on 31 May 2021 and had spread to over 179 countries by 22 November 2021. The World Health Organization (WHO) indicated in June 2021 that the Delta variant was becoming the dominant strain globally.

Civet SARS-CoV is a coronavirus associated with severe acute respiratory syndrome coronavirus (SARS-CoV), which infected humans and caused SARS events from 2002 to 2003. It infected the masked palm civet. The severe acute respiratory syndrome coronavirus (SARS-CoV) is highly similar, with a genome sequence similarity of about 99.8%. Because several patients infected at the early stage of the epidemic had contact with fruit-eating Japanese raccoon dog in the market, tanuki may be a direct source of human SARS coronavirus. At the end of 2003, four more people in Guangzhou, China, were infected with the disease. Sequence analysis found that the similarity with the tanuki virus reached 99.9%, and the SARS coronavirus was also caused by cases of tanuki transmission.

<span class="mw-page-title-main">SARS-CoV-2 Kappa variant</span> Type of the virus detected in 2020

Kappa variant is a variant of SARS-CoV-2, the virus that causes COVID-19. It is one of the three sublineages of Pango lineage B.1.617. The SARS-CoV-2 Kappa variant is also known as lineage B.1.617.1 and was first detected in India in December 2020. By the end of March 2021, the Kappa sub-variant accounted for more than half of the sequences being submitted from India. On 1 April 2021, it was designated a Variant Under Investigation (VUI-21APR-01) by Public Health England.

Lineage B.1.617 is a lineage of SARS-CoV-2, the virus that causes COVID-19. It first came to international attention in late March 2021 after the newly established INSACOG performed genome sequencing on positive samples throughout various Indian states. Analysis of samples from Maharashtra had revealed that compared to December 2020, there was an increase in the fraction of samples with the E484Q and L452R mutations. Lineage B.1.617 later came to be dubbed a double mutant by news media.

<span class="mw-page-title-main">Coronavirus spike protein</span> Glycoprotein spike on a viral capsid or viral envelope

Spike (S) glycoprotein is the largest of the four major structural proteins found in coronaviruses. The spike protein assembles into trimers that form large structures, called spikes or peplomers, that project from the surface of the virion. The distinctive appearance of these spikes when visualized using negative stain transmission electron microscopy, "recalling the solar corona", gives the virus family its main name.

Christopher O. Barnes is an American chemist who is an assistant professor at Stanford University. During the COVID-19 pandemic, he studied the structure of the coronavirus spike protein and the antibodies that attack them. He was named one of ten "Scientists to watch" by Science News in 2022.

References

  1. 1 2 3 "Jesse Bloom, Ph.D." Fred Hutch. Retrieved 2022-05-18.
  2. 1 2 "Jesse D. Bloom". HHMI. Retrieved 2022-10-29.
  3. ↑ "Jesse D. Bloom | UW Microbiology". microbiology.washington.edu. Retrieved 2022-10-29.
  4. ↑ "UW Genome Sciences: Jesse Bloom". www.gs.washington.edu. Retrieved 2022-10-29.
  5. ↑ "Jesse Bloom". www.aiche.org. 2021-03-05. Retrieved 2022-10-29.
  6. ↑ "Jesse Bloom, Ph.D." Fred Hutch. Retrieved 2022-12-17.
  7. ↑ "Jesse D. Bloom". HHMI. Retrieved 2022-12-17.
  8. 1 2 Thyagarajan, Bargavi; Bloom, Jesse D (2014-07-08). Pascual, Mercedes (ed.). "The inherent mutational tolerance and antigenic evolvability of influenza hemagglutinin". eLife. 3: e03300. doi: 10.7554/eLife.03300 . ISSN   2050-084X. PMC   4109307 . PMID   25006036.
  9. ↑ Haddox, Hugh K.; Dingens, Adam S.; Bloom, Jesse D. (2016-12-13). "Experimental Estimation of the Effects of All Amino-Acid Mutations to HIV's Envelope Protein on Viral Replication in Cell Culture". PLOS Pathogens. 12 (12): e1006114. doi: 10.1371/journal.ppat.1006114 . ISSN   1553-7374. PMC   5189966 . PMID   27959955.
  10. 1 2 3 4 Starr, Tyler N.; Greaney, Allison J.; Hilton, Sarah K.; Ellis, Daniel; Crawford, Katharine H. D.; Dingens, Adam S.; Navarro, Mary Jane; Bowen, John E.; Tortorici, M. Alejandra; Walls, Alexandra C.; King, Neil P.; Veesler, David; Bloom, Jesse D. (2020-09-03). "Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding". Cell. 182 (5): 1295–1310.e20. doi:10.1016/j.cell.2020.08.012. ISSN   0092-8674. PMC   7418704 . PMID   32841599.
  11. ↑ Eguia, Rachel T.; Crawford, Katharine H. D.; Stevens-Ayers, Terry; Kelnhofer-Millevolte, Laurel; Greninger, Alexander L.; Englund, Janet A.; Boeckh, Michael J.; Bloom, Jesse D. (2021-04-08). Lauring, Adam S. (ed.). "A human coronavirus evolves antigenically to escape antibody immunity". PLOS Pathogens. 17 (4): e1009453. doi: 10.1371/journal.ppat.1009453 . ISSN   1553-7374. PMC   8031418 . PMID   33831132.
  12. ↑ Dadonaite, Bernadeta; Crawford, Katharine H. D.; Radford, Caelan E.; Farrell, Ariana G.; Yu, Timothy C.; Hannon, William W.; Zhou, Panpan; Andrabi, Raiees; Burton, Dennis R.; Liu, Lihong; Ho, David D.; Neher, Richard A.; Bloom, Jesse D. (2022-10-13). "A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike". bioRxiv   10.1101/2022.10.13.512056 .
  13. 1 2 Starr, Tyler N.; Greaney, Allison J.; Addetia, Amin; Hannon, William W.; Choudhary, Manish C.; Dingens, Adam S.; Li, Jonathan Z.; Bloom, Jesse D. (2021-02-19). "Prospective mapping of viral mutations that escape antibodies used to treat COVID-19". Science. 371 (6531): 850–854. Bibcode:2021Sci...371..850S. doi:10.1126/science.abf9302. ISSN   0036-8075. PMC   7963219 . PMID   33495308.
  14. ↑ Greaney, Allison J.; Loes, Andrea N.; Crawford, Katharine H. D.; Starr, Tyler N.; Malone, Keara D.; Chu, Helen Y.; Bloom, Jesse D. (2021-03-10). "Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies". Cell Host & Microbe. 29 (3): 463–476.e6. doi:10.1016/j.chom.2021.02.003. ISSN   1931-3128. PMC   7869748 . PMID   33592168.
  15. ↑ Greaney, Allison J; Starr, Tyler N; Bloom, Jesse D (2022-05-11). "An antibody-escape estimator for mutations to the SARS-CoV-2 receptor-binding domain". Virus Evolution. 8 (1): veac021. doi:10.1093/ve/veac021. ISSN   2057-1577. PMC   9092643 . PMID   35573973.
  16. 1 2 Starr, Tyler N.; Zepeda, Samantha K.; Walls, Alexandra C.; Greaney, Allison J.; Alkhovsky, Sergey; Veesler, David; Bloom, Jesse D. (March 2022). "ACE2 binding is an ancestral and evolvable trait of sarbecoviruses". Nature. 603 (7903): 913–918. Bibcode:2022Natur.603..913S. doi:10.1038/s41586-022-04464-z. ISSN   1476-4687. PMC   8967715 . PMID   35114688.
  17. ↑ Starr, Tyler N.; Czudnochowski, Nadine; Liu, Zhuoming; Zatta, Fabrizia; Park, Young-Jun; Addetia, Amin; Pinto, Dora; Beltramello, Martina; Hernandez, Patrick; Greaney, Allison J.; Marzi, Roberta; Glass, William G.; Zhang, Ivy; Dingens, Adam S.; Bowen, John E. (September 2021). "SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape". Nature. 597 (7874): 97–102. Bibcode:2021Natur.597...97S. doi: 10.1038/s41586-021-03807-6 . ISSN   1476-4687. PMC   9282883 . PMID   34261126. S2CID   235907733.
  18. ↑ Cobey, Sarah; Bloom, Jesse; Starr, Tyler; Lash, Nathaniel (2022-03-28). "Opinion | We Study Virus Evolution. Here's Where We Think the Coronavirus Is Going". The New York Times. ISSN   0362-4331 . Retrieved 2022-12-17.
  19. ↑ Bloom, Jesse; Cobey, Sarah (2021-12-12). "Opinion | A Scientist's Guide to Understanding Omicron". The New York Times. ISSN   0362-4331 . Retrieved 2022-12-17.
  20. ↑ Bloom, Jesse (2022-10-30). "Opinion | A Plea for Making Virus Research Safer". The New York Times. ISSN   0362-4331 . Retrieved 2022-12-17.
  21. ↑ Bloom, Jesse D.; Chan, Yujia Alina; Baric, Ralph S.; Bjorkman, Pamela J.; Cobey, Sarah; Deverman, Benjamin E.; Fisman, David N.; Gupta, Ravindra; Iwasaki, Akiko; Lipsitch, Marc; Medzhitov, Ruslan; Neher, Richard A.; Nielsen, Rasmus; Patterson, Nick; Stearns, Tim (2021-05-14). Sills, Jennifer (ed.). "Investigate the origins of COVID-19". Science. 372 (6543): 694. Bibcode:2021Sci...372..694B. doi:10.1126/science.abj0016. ISSN   0036-8075. PMC   9520851 . PMID   33986172.
  22. ↑ ""This Shouldn't Happen": Inside the Virus-Hunting Nonprofit at the Center of the Lab-Leak Controversy". Vanity Fair. 2022-03-31. Retrieved 2022-05-18.
  23. ↑ Bloom, Jesse D (2021-12-09). Nielsen, Rasmus (ed.). "Recovery of Deleted Deep Sequencing Data Sheds More Light on the Early Wuhan SARS-CoV-2 Epidemic". Molecular Biology and Evolution. 38 (12): 5211–5224. doi:10.1093/molbev/msab246. ISSN   1537-1719. PMC   8436388 . PMID   34398234.
  24. ↑ "McDougall Mentoring Award" (PDF). Jan 6, 2022.
  25. ↑ "Jesse Bloom, PhD". HHMI. Retrieved 2022-10-29.
  26. ↑ "Good News: Malik and Bloom win ASM awards; pilot project funded by Bezos family aims to create personalized anticancer vaccines". Fred Hutch. 2016-11-14. Retrieved 2022-12-17.
  27. ↑ "Ann Palmenberg Junior Investigator Award". American Society for Virology. Retrieved 2022-12-17.
  28. ↑ "People". Simons Foundation. Retrieved 2022-10-29.
  29. ↑ Vazquez, Franck (2015-02-17). "The 2015 Viruses Young Investigator Prize Has Been Awarded!". MDPI Blog. Retrieved 2022-12-17.
  30. ↑ Trusts, The Pew Charitable. "Pew Names 22 Top Scientists as Scholars in the Biomedical Sciences". www.prnewswire.com (Press release). Retrieved 2022-12-17.
  31. ↑ "Scholar Profile Jesse D. Bloom". Searle Scholars Program. Archived from the original on September 5, 2015. Retrieved 2 June 2023.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.